Generalized Anxiety Disorder - Epidemiology Forecast to 2030

DelveInsight’s ‘Generalized Anxiety Disorder (GAD)- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted GAD epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Generalized Anxiety Disorder (GAD) Understanding
Generalized Anxiety Disorder (GAD) is characterized by persistent and exaggerated anxiety and worry about everyday life events with no obvious reasons for worry. People with GAD may anticipate disaster and may be overly concerned about money, health, family, work, or other issues. Individuals with GAD find it difficult to control their worry. They may worry more than seems warranted about actual events or may expect the worst even when there is no apparent reason for concern. According to Anxiety and Depression Association of America (ADAA), GAD affects around 6.8 million adults or 3.1% of the US adult population in any given year and the criteria used for diagnosis was based on DSM-IV. However, latest DSM-V yielded an influx of new GAD cases which give rise to the prevalence rate as well in adult population (i.e., 12-month prevalence rate is 4% in the US adult population). Women are twice as likely to be affected. GAD can begin at any point in the life cycle but usually develops between childhood and middle age. People with GAD experience a combination of emotional, behavioral, and physical symptoms that often fluctuate, becoming worse at times of stress. The anxiety is often associated with physical symptoms, such as sleep disturbance, restlessness, muscle tension, gastrointestinal symptoms, and chronic headaches and others. It also includes several psychological symptoms.

Epidemiology Perspective by DelveInsight
The GAD epidemiology division provides insights about historical and current patient pool and forecasted trends for each seven major countries. The GAD epidemiology data are studied through GAD possible division to give a better understanding of the Disease scenario in the 7MM.

The disease epidemiology covered in the report provides historical as well as forecasted GAD epidemiology [segmented as Total 12-Month Prevalent Cases of GAD, Total Gender-Specific Cases of GAD, Total Age-Specific Cases of GAD, Total Severity -Specific Cases of GAD (Children/Adolescents, and Adults),] scenario of GAD in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

GAD Detailed Epidemiology Segmentation
• The Total 12-Month Prevalent Cases of GAD in 7MM was 16,606,987 in 2017, based on DSM-V criteria. Estimates show that the United States accounted for the highest number of cases of GAD among all the 7MM countries, i.e., 11,113,727. Among the EU5, France has the highest prevalence with estimated 1,304,965 cases in 2017.
• In 2017, there were a total of 4,083,434 cases of GAD in the age-group (18–24), and 685,341 cases in 65 and above, in the United States.
• The severity of GAD Is divided into mild, moderate, or severe based on the number of criteria symptoms such as a functional disability in work role performance, household maintenance, social life, and intimate relationships with the severity of the symptoms.
• In 2017, there were 238,201 mild cases, 459,904 moderate cases and 333,070 severe cases of GAD in the US. The overall children and adolescent specific severity specific cases of GAD are subjected to increase in the coming years.

Scope of the Report
• The GAD report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
• The GAD Report and Model provide an overview of the risk factors and global trends of GAD in the seven major markets (7MM: United States, Germany, France, Italy, Spain, and the United Kingdom, and Japan).
• The report provides insight about the historical and forecasted patient pool of GAD in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of GAD.
• The report provides the segmentation of the GAD epidemiology by total 12-Month Prevalent Cases of GAD in the 7MM.
• The report provides the segmentation of the GAD epidemiology by Age and Gender in the 7MM.
• The report provides the segmentation of the GAD epidemiology by Severity-Specific in the 7MM.

Report Highlights
• 11-Year Forecast of GAD epidemiology
• 7MM Coverage
• Total 12-Month Prevalent Cases of GAD in the 7MM
• Prevalent Cases of GAD according to segmentation:Age, Gender, and Severity (Children and Adolescents and Adults)

KOL-Views
We interview, KOL’s and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overGADscenario of the indications.

Key Questions Answered
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to GAD?
• What are the key findings pertaining to the GAD epidemiology across the 7MM and which country will have the highest number of patients during the study period (2017–2030)?
• What would be the total number of patients across the 7MM during the study period (2017–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the study period (2017–2030)?
• At what CAGR the patient population is expected to grow in the 7MM during the study period (2017–2030)?
• What are the various recent and upcoming events which are expected to improve the diagnosis of GAD?

Reasons to buy
The GAD epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global GADmarket
• Quantify patient populations in the global GAD market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for GAD therapeutics in each of the markets covered
• Understand the magnitude of GAD population by its severity
• The GAD epidemiology report and model were written and developed by Masters and PhD level epidemiologists
• The GAD epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population
Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017–2030
Total ptevalent cases of GAD in the United States was assessed to be 11,113,727 in 2017, and are expected to decline during the study period. The severity of GAD Is divided into mild, moderate, or severe based on the number of criteria symptoms such as a functional disability in work role performance, household maintenance, social life, and intimate relationships with the severity of the symptoms. According to DelveInsight’s analysts, the age-specific data in adults, 18–29 is normally reported with the initiation of the anxiety symptoms, thus then increased with middle age group (30–44) and to 45–59 years, while older (60+) age group are the least affected. This may be often associated with societal responsibilities and personal satisfaction levels.